A Sugar Made by Gut Bacteria Quietly Dismantles Melanoma Tumors in Mice

A simple sugar secreted by a probiotic gut bacterium may be quietly remodeling the immune landscape inside melanoma tumors. Preliminary research in mice suggests that mannose, a metabolite produced by Bifidobacterium animalis, activates the killer T cells that anti-cancer immunotherapy depends on, and may help overcome the resistance that currently defeats treatment in more than half of melanoma patients. The findings are early, confined to animal models, and carry real caveats, but they point toward a genuinely novel angle on one of oncology's most frustrating problems.

Why More Than Half of Melanoma Patients Stop Responding to Immunotherapy

Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 pathway have transformed melanoma treatment over the past decade. By releasing a molecular brake on the immune system, these drugs can drive durable remissions in tumors that once carried grim prognoses. Yet more than 50% of patients develop primary or acquired resistance, and the tumor immune microenvironment, the mix of immune and stromal cells surrounding a tumor, is a key determinant of whether therapy succeeds. A growing body of evidence links that microenvironment to the gut: melanoma patients consistently show reduced microbial diversity and, specifically, depleted levels of beneficial Bifidobacterium species. Patients who respond to anti-PD-1 therapy tend to have higher Bifidobacterium abundance in their gut, and fecal microbiota transplants from responders can partially restore ICI sensitivity in preclinical models.

Bifidobacterium animalis Suppresses B16-F10 Melanoma Tumors in Mice

Researchers isolated Bifidobacterium animalis (Ba) from healthy human feces and tested it in a B16-F10 syngeneic murine melanoma model, one of the most widely used preclinical systems for studying tumor immunology in mice. Ba treatment suppressed tumor growth both in cell culture and in living mice. Profiling the tumor immune microenvironment revealed a striking immune shift: Ba upregulated 22 inflammation-related genes, including chemokines associated with CD8+ T cell and NK cell recruitment (Cxcl9, Cxcl11, Ccl19, Ccr7), while significantly reducing myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages, and regulatory T cells. All of those suppressive cell types are known to blunt anti-tumor immunity. Critically, Ba conditioned medium (Ba.CM) directly activated CD8+ T cells in culture, boosting expression of the cytotoxic molecule granzyme B (GZMB) and the inflammatory cytokines IFN-gamma and TNF-alpha. Filtering experiments showed the active molecules in Ba.CM are non-proteinaceous and smaller than 3 kilodaltons, narrowing the search to small metabolites rather than proteins.

Mannose Enters CD8+ T Cells and Silences an Anti-Immunity Protein Called YAP1

Untargeted metabolomic profiling of Ba.CM and fecal samples from Ba-treated mice identified mannose as the most prominently enriched metabolite. When researchers administered 1% mannose orally to tumor-bearing mice, serum and tumor mannose levels rose to amounts comparable to direct Ba gavage. The treatment increased intratumoral CD8+ T cells and their production of GZMB, TNF-alpha, and IFN-gamma. Depleting CD8+ T cells almost completely abolished mannose's anti-tumor effect, confirming that the benefit runs through those immune cells rather than through direct toxicity to cancer cells.

The mechanistic picture that emerged centers on YAP1, a transcriptional co-activator in the Hippo signaling pathway. When YAP1 translocates to the nucleus of a T cell, it restricts cytotoxic function. Mannose enters CD8+ T cells primarily via the glucose transporter GLUT1, activates the Hippo pathway, promotes YAP1 phosphorylation at Serine 127, and prevents its nuclear translocation. Blocking GLUT1 with the specific inhibitor BAY-876 abolished mannose's effects on both T cell function and YAP1 regulation, tying the mechanism to a defined entry route. Gene set enrichment analysis of mannose-treated CD8+ T cells confirmed significant enrichment of the Hippo signaling gene set. Separately, mannose may also inhibit glycolysis and improve mitochondrial fitness in T cells, adding a metabolic dimension to its immunostimulatory effects.

Combining Ba With Anti-PD-1 Therapy Amplified Tumor Suppression

The translational payoff came when researchers combined Ba gavage with anti-PD-1 antibody treatment in the same B16-F10 model. The combination produced significantly greater tumor suppression and higher intratumoral CD8+ T cell infiltration and activation than either treatment alone. Mannose also selectively enriched beneficial gut bacteria, including Lactobacillus species, Ba itself, Bifidobacterium pseudocatenulatum, and Lactobacillus rhamnosus, without broadly perturbing the microbiome. Whether this microbial reshaping reflects a direct prebiotic effect of mannose or arises secondarily from reduced tumor burden remains an open question.

Open Questions Before This Approach Can Move Toward the Clinic

The study was conducted entirely in mice using the B16-F10 model, which is highly immunogenic and may not capture the heterogeneity of human melanoma. The authors acknowledge that mannose-mediated immunomodulation has not been tested in low-immunogenicity or spontaneous tumor models. YAP1 plays context-dependent roles in T cell biology, including effects on proliferation and metabolic adaptation, that the current work did not fully explore. The pharmacokinetics of oral mannose in humans, including how much reaches the tumor microenvironment and at what doses, requires dedicated clinical investigation. And while live Ba carries an established safety record as a probiotic, its use in severely immunosuppressed patients warrants extra caution.

The broader field of microbial therapeutics in cancer is at a pivotal moment: translating promising preclinical signals into structured human trials demands standardized protocols and careful patient stratification. Some steps are already underway. An active clinical trial is evaluating Bifidobacterium animalis lactis BL-04 alongside immunotherapy in patients with metastatic non-small cell lung cancer, providing a nearby benchmark for how probiotic-ICI combinations perform in humans.

For melanoma specifically, the mannose finding opens an intriguing question: if a metabolite this small and this well-tolerated can reprogram the tumor immune microenvironment through a defined molecular mechanism, it may be possible to deliver the benefit without the variability of live bacteria. Oral mannose is already used clinically for a rare metabolic disorder, so its safety profile in humans is not entirely unknown. What remains entirely unknown is whether the YAP1-suppressing, CD8-activating effect observed in mice will translate, or at what dose, in cancer patients. That is the work ahead.

Evidence rating

INVESTIGATIONAL — 73/100

Caveats:

• All in vivo experiments were conducted in mice using the B16-F10 syngeneic melanoma model; results have not been tested in humans.
• No funding source was disclosed, so potential conflicts of interest cannot be assessed.
• Single study with no independent replication; findings should be considered preliminary.
• The B16-F10 model is highly immunogenic and may not reflect the full heterogeneity of human melanoma.

Preclinical study using a syngeneic murine melanoma model and in vitro assays. Demonstrates a mechanistic causal chain but cannot establish efficacy or safety in humans. No independent replication exists, and the highly immunogenic B16-F10 model may not generalize to human melanoma biology.

References

1. Chengyi Li, Xuehua Zhang, Yichen Yang, et al. (2026). <italic>Bifidobacterium animalis</italic> suppresses melanoma progression and activates anti-tumor immunity by inhibiting YAP1 expression in CD8^&#x002B; T cells. Cancer Biology & Medicine. https://doi.org/10.20892/j.issn.2095-3941.2025.0652
2. Mouse models for cancer research – PMC – NIH. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905391/
3. Bantayehu Addis Tegegne, Desalegn Abebaw, Zigale Hibstu Teffera, et al. (2025). Microbial Therapeutics in Cancer: Translating Probiotics, Prebiotics, Synbiotics, and Postbiotics From Mechanistic Insights to Clinical Applications: A Topical Review. The FASEB Journal. https://doi.org/10.1096/fj.202502118r
4. The Impact of Probiotic on Survival and Treatment Response in Metastatic Non-small Cell Lung Cancer Patients. clinicaltrials.gov. https://clinicaltrials.gov/study/NCT06428422